Screener
BridgeBio Pharma BBIO Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Unpaid property and equipment | $12 | $337 |
| Transfers to noncontrolling interests | $(1,955) | $(824) |
| Recognized intangible asset recorded to “Other current liabilities” | — | $4,500 |
| Reconciliation of Cash, Cash Equivalents and Restricted Cash: | ||
| Cash and cash equivalents | $879,891 | $540,599 |
| Restricted cash — Included in “Prepaid expenses and other current assets” | 550 | 126 |
| Restricted cash — Included in “Other assets” | 1,577 | 2,017 |
| Total cash, cash equivalents and restricted cash at end of periods shown on the condensed consolidated statements of cash flows | $882,018 | $542,742 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's restricted cash?
- BridgeBio Pharma (BBIO) reported restricted cash of $550K in Q1 2026.
- How has BridgeBio Pharma's restricted cash changed year-over-year?
- BridgeBio Pharma's restricted cash increased by 336.5% year-over-year, from $126K to $550K.
- What is the long-term trend for BridgeBio Pharma's restricted cash?
- Over 4 years (2020 to 2024), BridgeBio Pharma's restricted cash has grown at a -2.4% compound annual growth rate (CAGR), from $139K to $126K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about BridgeBio Pharma's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude